Boehringer Ingelheim are now setting up for a Phase I trial to test how BI 1467335 is taken up in the body of people with Normal Kidney Function and people with Reduced Kidney Function. The study also will look at how well the participants (~20) tolerate the drug.
https://clinicaltrials.gov/ct2/show/NCT03302091?term=BI1467335&rank=6
- Forums
- ASX - By Stock
- SNT
- Ann: Boehringer Initiating Phase 2a Study Diabetic Retinopathy
Ann: Boehringer Initiating Phase 2a Study Diabetic Retinopathy, page-24
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SNT (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $44.17M |
Open | High | Low | Value | Volume |
3.9¢ | 4.0¢ | 3.7¢ | $66.77K | 1.752M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2713 | 3.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.0¢ | 209403 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 493 | 0.039 |
3 | 202932 | 0.037 |
4 | 451544 | 0.036 |
6 | 1278604 | 0.035 |
1 | 200000 | 0.034 |
Price($) | Vol. | No. |
---|---|---|
0.040 | 209403 | 1 |
0.043 | 25000 | 1 |
0.045 | 45224 | 1 |
0.046 | 70076 | 2 |
0.047 | 33889 | 1 |
Last trade - 14.38pm 24/07/2024 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
Previous Video
Next Video
SPONSORED BY The Market Online